Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02049138
Recruitment Status : Active, not recruiting
First Posted : January 30, 2014
Last Update Posted : January 13, 2020
Sponsor:
Information provided by (Responsible Party):
AbbVie

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a Phase 2, multicenter, open-label extension study in RA subjects. The sub-study is to assess the impact of upadacitinib treatment (15 mg QD and 30 mg QD) with background MTX on immunological responses to Prevnar 13® in RA patients.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: ABT-494 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 494 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)
Actual Study Start Date : January 24, 2014
Estimated Primary Completion Date : July 24, 2021
Estimated Study Completion Date : July 24, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Open-label extension
All subjects will start treatment with ABT-494.
 Drug: ABT-494
Tablet; Oral
Other Names:
  • Upadacitinib
  • Rinvoq


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Change in Work Instability Scale - Rheumatoid Arthritis (RA-WIS) [ Time Frame: From Week 0 to Week 312 ]
    Using RA-WIS scale

  2. Change in EQ-5D [ Time Frame: From Week 0 to Week 312 ]
    Using the EuroQol-5D scale

  3. ACR 70 Response Rate [ Time Frame: Up to Week 312 ]
    ACR criteria measures improvement in tender or swollen joint counts.

  4. Change in Health Assessment Questionnaire Disability Index [ Time Frame: From Week 0 to Week 312 ]
    Determined by the Health Assessment Questionnaire (HAQ-DI)

  5. Change in High-Sensitivity C-Reactive Protein (hsCRP) [ Time Frame: From Week 0 to Week 312 ]
    Determined by hsCRP lab test

  6. Change in Patient's Global Assessment of Disease Activity [ Time Frame: From Week 0 to Week 312 ]
    Determined by VAS

  7. Change in DAS28 [CRP] [ Time Frame: From Week 0 to Week 312 ]
    DAS28 [CRP] calculation

  8. Change in Patient's Assessment of Pain [ Time Frame: From Week 0 to Week 312 ]
    Determined by the Joint Evaluation, Visual Analog Scale (VAS), EuroQoL-5D (EQ-5D)

  9. Change in Swollen Joint Count [ Time Frame: From Week 0 to Week 312 ]
    Swollen Joint Count will be assessed by a qualified Independent Joint Assessor or Principal Investigator using the Joint Evaluation Worksheet.

  10. Change in CDAI [ Time Frame: From Week 0 to Week 312 ]
    The sum of tender and swollen joint counts [28 joints] and patient and physician global assessments

  11. ACR 50 Response Rate [ Time Frame: Up to Week 312 ]
    ACR criteria measures improvement in tender or swollen joint counts.

  12. Proportion of subjects achieving Low Disease Activity [ Time Frame: Up to Week 312 ]
    Determined by disease activity score using 28 joint counts (DAS28) [CRP] or clinical disease activity index (CDAI) criteria

  13. Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Scale [ Time Frame: From Week 0 to Week 312 ]
    Using the FACIT Fatigue Scale

  14. American College Rheumatology (ACR) 20 Response Rate [ Time Frame: Up to Week 312 ]
    ACR criteria measures improvement in tender or swollen joint counts.

  15. Proportion of subjects achieving Clinical Remission [ Time Frame: Up to Week 312 ]
    Determined by DAS28 [CRP] and CDAI criteria

  16. Change in Tender Joint Count [ Time Frame: From Week 0 to Week 312 ]
    Tender Joint Count will be assessed by a qualified Independent Joint Assessor or Principal Investigator using the Joint Evaluation Worksheet.

  17. Change in Clinical Laboratory Data [ Time Frame: From Week 0 through 30 day follow-up visit (30 days after last dose of study drug) ]
    Clinical Laboratory Data include hematology, clinical chemistry and urinalysis

  18. Proportion of subjects with satisfactory humoral response to Prevnar 13 [ Time Frame: Week 4 of the sub-study (approximately 136 weeks) ]
    Satisfactory response is defined as greater than or equal to 2-fold increase in antibody concentration from the vaccination baseline in at least 6 out of the 12 pneumococcal antigens.


Secondary Outcome Measures :
  1. Proportion of subjects with satisfactory humoral response to Prevnar 13 [ Time Frame: Week 12 of the sub-study (approximately 252 weeks) ]
    Satisfactory response is defined as greater than or equal to 2-fold increase in antibody concentration from the vaccination baseline in at least 6 out of the 12 pneumococcal antigens

  2. Change in geometric mean fold rise of anti-pneumococcal antibody levels [ Time Frame: Up to Week 12 of the sub-study (approximately 252 weeks) ]
    Anti-pneumococcal antibody levels to each of the 12 pneumococcal antigens above vaccination baseline values.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects who have completed Study M13-550 or Study M13-537 with Upadacitinib (ABT-494) and has not developed any discontinuation criteria.
  2. If the subject has evidence of new latent Tuberculosis (TB) infection, the subject must initiate and complete a minimum of 2 weeks (or per local guidelines, whichever is longer) of an ongoing TB prophylaxis before continuing to receive study drug.

  3. If female, subject must meet one of the following criteria:

    • Postmenopausal (defined as no menses for at least 1 year).
    • Surgically sterile (bilateral oophorectomy or hysterectomy).

    • Practicing from the time of screening until at least 30 days after the last dose of study drug at least TWO of the following methods of birth control:

      1. Tubal ligation
      2. Partner vasectomy (at least 6 months earlier) (the vasectomized male partner should be the sole partner for that female subject)
      3. Intrauterine device
      4. A male condom with spermicidal jelly or cream
      5. Diaphragm, contraceptive sponge or cervical cap with spermicidal jelly or cream
      6. Hormonal contraceptives (injected, oral, transdermal or implanted methods) must have been taking at least 2 months prior to dosing
  4. Male subjects must agree to follow protocol-specified pregnancy avoidance measures, including refraining from donating sperm, for up to 30 days post last dose of study drug.
  5. Subjects must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.

Substudy:

  1. Must currently be enrolled in the main study.
  2. Must have been receiving a stable dose of upadacitinib (either 15 mg QD or 30 mg QD) for a minimum of 4 weeks prior to the Vaccination visit.
  3. Must have been on a stable dose of background methotrexate (no change in dose or frequency) for a minimum of 4 weeks prior to the Vaccination visit.
  4. If subject is on corticosteroids, must remain on a stable dose of ≤ 10 mg/day of prednisone or equivalent corticosteroid therapy for at least 4 weeks after the vaccination visit.
  5. Must meet the prescribing specifications as per local label requirements to receive Prevnar 13® vaccine.
  6. Willing to receive Prevnar13® vaccine.

Exclusion Criteria:

  1. Pregnant or breastfeeding female.
  2. Ongoing infections at Week 0 that have NOT been successfully treated. Subjects with ongoing infections undergoing treatment may be enrolled BUT NOT dosed until the infection has been successfully treated.
  3. Anticipated requirement or receipt of any live vaccine during study participation including up to 30 days after the last dose of study drug.

  4. Laboratory values from the visit immediately prior to Baseline Visit (local requirements may apply) meeting the following criteria:

    • Serum aspartate transaminase (AST) or alanine transaminase (ALT) > 3.0 × Upper Limit of Normal (ULN)
    • Estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease (MDRD) formula < 40mL/min/1.73m2
    • Total white blood cell count (WBC) < 2,000/μL
    • Absolute neutrophil count (ANC) < 1,000/μL
    • Platelet count < 50,000/μL
    • Absolute lymphocytes count < 500/μL
    • Hemoglobin < 8 gm/dL
  5. Enrollment in another interventional clinical study while participating in this study.
  6. Consideration by the investigator, for any reason, that the subject is an unsuitable candidate to receive study drug.

Substudy:

  1. Receiving any csDMARDs other than MTX
  2. Receiving > 10 mg/day of prednisone or equivalent corticosteroid therapy.
  3. Receipt of any steroid injection within 4 weeks prior to Vaccination visit.
  4. History of severe allergic reaction (e.g., anaphylaxis) to any component of Prevnar 13®.
  5. History of any documented pneumococcal infection within the last 6 months prior to the vaccination visit.
  6. Receipt of any vaccine 4 weeks prior to the vaccination visit and/or anticipation of any vaccination for 4 weeks after the vaccination visit.
  7. Receipt of any pneumococcal vaccine.
  8. Subject is not suitable for the sub-study as per the Investigator's judgment.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02049138


Locations
Show Show 124 study locations
Sponsors and Collaborators
AbbVie
Investigators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT02049138    
Other Study ID Numbers: M13-538
2013-003530-33 ( EudraCT Number )
First Posted: January 30, 2014    Key Record Dates
Last Update Posted: January 13, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access Criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
URL: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Musculoskeletal Disease
Arthritis
Joint Diseases
Anti-inflammatory Agents
Antirheumatic agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
 Immune System Diseases
Upadacitinib
Janus Kinase Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents